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Summary : First reported in 1979, anaesthetists now
encounter more and more patients with latex allergy.
Several risk groups prone to develop this allergy have
been identified. A thorough preoperative interview is
necessary to detect high-risk patients. For them, the peri-
operative period is very dangerous because of the many
possibilities of contact with latex-containing materials.
There is no cure for latex allergy. Absolute avoidance of
contact with latex is the only safe way to treat those who
belong to a risk group or who are already allergic. The
diagnosis of latex allergy must be kept in mind in every
case of perioperative anaphylaxis, even if the patient
does not belong to a risk group. In the future, desensiti-
zation will probably be useful in helping patients with
latex allergy.
INTRODUCTION
Anaphylactic and anaphylactoid reactions
occurring during anaesthesia remain a major cause
of concern for anaesthetists. The incidence of
severe anaphylaxis during general anaesthesia is
1/6000-1/10000. Mortality is about 6% (1). The
most common causes of anaphylaxis are neuromus-
cular blocking agents (58.2%), latex (16.7%) and
antibiotics (15.1%) (2). 
Since its first recognition in 1979 (3), anaes-
thetists are encountering latex allergy much more
frequently (4). Latex is now the second most com-
mon cause of anaphylaxis during anaesthesia. In
children with spina bifida, it is the most important
cause of anaphylactic reactions (5, 6). 
ORIGIN NATURAL RUBBER LATEX (NRL)
NRL is a milky fluid obtained primarily from
the rubber tree, Hevea brasiliensis ; 95% of the
world’s natural rubber supply is produced in
Asia (7). Liquid NRL comprises water (55-65%),
cis-1,4-polyisoprene rubber (34%), proteins (2-3%)
and small amounts of sugars, sterol glycosides,
resins and ash. The proteins cause the IgE-mediat-
ed latex allergy (8). 
NRL ALLERGENS
Hevea brasiliensis (Hev b) latex contains sev-
eral well-characterized proteins ; 13 Hev b proteins
are known at present (Hev b1-b13) (9). Hev b1 and
b3 are the most important allergens for patients
with spina bifida and other congenital disorders that
require multiple operations in childhood (10, 11).
Healthcare workers are more frequently sensitized
to Hev b2, b4, b5 and b6 (12, 13).
NRL IN HOSPITAL
To reduce the spread of HIV, hepatitis B and C
in the 1980s, the Food and Drug Administration
(FDA) recommended that healthcare workers
should wear gloves to protect themselves. At the
same time the incidence of latex allergy increased.
Latex gloves are the main source of latex proteins
and are implicated in most cases of latex-mediated
reactions (14-20). There are enormous variations in
the amount of latex proteins in gloves from differ-
ent manufacturers and even in gloves from the same
manufacturer (14, 21-24). There are no government
regulations that require glove companies to label
the protein content. Cornstarch, the powder in latex
gloves, is not itself allergenic, but binds latex pro-
teins and acts as a vector for the aerogenic spread of
latex proteins. At the time of putting on and espe-
cially pulling out the gloves, the cornstarch parti-
cles with the latex proteins are released into the air,
are inhaled and may lead to conjunctival, nasal and
respiratory symptoms, and even to an anaphylactic
reaction (25). The air of rooms where powdered
latex gloves are used contains high concentrations
of latex allergens. These concentrations are lower
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blister formation (36). The extent of the reaction
depends on the duration of exposure and the skin
temperature. 
2. Allergic contact dermatitis or delayed cell-medi-
ated hypersensitivity reaction (Type IV)
This delayed immunological reaction is the
result of a T-cell mediated sensitivity to the chemi-
cal additives (antioxidants and accelerators), which
are absorbed through the skin. The lesions can
extend outside the surface of contact. This reaction
is not life threatening and is more frequent than the
life threatening type I reaction. On repeated expo-
sure, the reaction starts 24-48 h after contact and
peaks after 48-72 h. Its clinical features resemble
those of irritant contact dermatitis. Symptoms usu-
ally resolve within three to four days after exposure
(37, 38). Each exposure may lead to increased sen-
sitization and a more severe reaction (9). Diagnosis
is made by patch tests to one of the antioxidants or
accelerators (39).
Neither irritant nor allergic contact dermatitis
are caused by latex proteins, but these two forms of
contact dermatitis damage the barrier function of
the skin and can promote and accelerate sensitiza-
tion to latex proteins (40).
3. IgE-mediated hypersensitivity reaction (Type I) :
the real latex allergy 
This is the least frequent but most dangerous
reaction, and the only latex-associated reaction
caused by the latex proteins. During first exposure,
IgE antibodies to Hev b proteins are produced by B-
lymphocytes. These IgEs bind to the surface of tis-
sue mast cells and blood basophils. Upon re-expo-
sure to latex, Hev b proteins cross-link membrane-
bound IgEs, leading to degranulation of the sensi-
tized mast cells and basophils. Preformed mediators
such as histamine and tryptase, and newly generat-
ed arachidonic acid metabolites (prostaglandins and
leukotrienes), are released, leading to symptoms
(41-45).
IgE-mediated latex allergy presents with
symptoms that differ between individuals. The reac-
tion ranges from mild symptoms (pruritus, cuta-
neous rash, urticaria, oedema of the eyes, rhinitis,
conjunctivitis, slight hypotension and tachycardia)
to a potential life threatening anaphylactic reaction
(laryngeal oedema, bronchospasm, asthma, angi-
oedema, cardiovascular collapse with bradycardia,
cardiac arrest and death) (2, 37). Several of these
symptoms often coincide, but they can also occur in
when non-powdered latex gloves are used (17, 18).
Latex is also found in many other materials used
perioperatively (Table I).
Owing to the increasing knowledge and con-
cerns about latex allergy, the industry has reduced
the amount of latex proteins in gloves and other
materials. Powdered gloves are less used. The
removal of the cornstarch powder is important
because it greatly reduces the concentration of latex
aeroallergens (27-33). For many products, latex-
free alternatives are available (34).
CLINICAL MANIFESTATIONS OF LATEX ALLERGY
Three different types of reactions can occur in
patients exposed to latex-containing materials :
1. Irritant contact dermatitis
The most frequent reaction associated with
latex gloves is irritant contact dermatitis, a non-
allergic reaction of the skin to an irritant. The alka-
line pH of most powdered gloves, sweating, the use
of disinfectants, mechanical irritation by the pow-
der and scrubbing are the most plausible causes for
this reaction (35). It can develop minutes to hours
after exposure to powdered latex gloves. It can
show up with the first exposure but is never life
threatening. The lesions are limited  to the surface
of contact. Symptoms include itching, skin rashes
or flakiness, burning sensations, inflammation or
Table I
Medical products that may contain latex protein (26)
Gloves (surgical gloves, non-sterile examination gloves etc.)
Intravascular devices 
- Balloon catheters
- Intravenous perfusion sets / intravenous tubing ports
- Syringe plungers
- Embolectomy catheters
- Swan-Ganz catheters
Airway equipment
- Nasopharyngeal airway
- Masks / elastic straps
- Endotracheal tubes
Tourniquets
Blood pressure cuffs / tubing
ECG leads
Pulse oximeter probes
Multidose medication tops
Condoms
Bladder catheters
Heating blankets
Gastrostomy devices
Blakemore tube
Tape
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isolation (2). The severity of the consecutive reac-
tions within one individual is unpredictable.
The moment of development of the IgE-medi-
ated reaction depends on the route of exposure to
the latex allergens. After inhalation of airborne par-
ticles, the proteins are absorbed slowly so symp-
toms develop after a delay of 30 to 60 min. Most of
the mild reactions such as local urticaria, rhinitis,
conjunctivitis and mild shortness of breath are the
result of inhalation of airborne latex particles.
Quick and severe reactions usually occur shortly
after parenteral or mucous membrane exposure to
latex proteins (mouth, vagina, urethra, rectum,
internal tissues during surgery) (46, 47). In
extremely allergic patients, inhalation of only very
small doses latex allergens causes a severe anaphy-
lactic reaction (17, 48).
RISK GROUPS FOR LATEX ALLERGY
The prevalence of latex allergy in the general
population is less than 1% (49, 50) and the preva-
lence of latex sensitization is between 5.4% and
7.6% (51). Unfortunately, many of these people do
not know they are sensitized to latex.
Several risk groups have a higher prevalence
for latex sensitization or allergy (Table II). In per-
sons with a history of atopy, a prevalence up to 17%
has been reported (54). Atopic persons frequently
have contact dermatitis and it is possible that this
may facilitate the transcutaneous passage of latex
proteins. Persons who have an allergy to tropical
fruit (such as avocado, kiwi, banana, mango, melon,
pineapple, papaya) and chestnut or hazelnut, are at
increased risk for latex allergy (prevalence of
11%) (34). These fruits contain proteins that are
structurally similar to latex proteins ; as a conse-
quence cross-sensitization can occur (53, 54). This
is called the latex-fruit syndrome.
Healthcare workers are also a high-risk group
because of frequent occupational contact with
latex-containing materials. Studies in healthcare
workers show a prevalence of sensitization of up to
17% (25, 55, 56). An atopic healthcare worker is at
even higher risk (57). 
Non-healthcare workers with occupational
exposure to latex, such as hairdressers (sensitization
prevalence 9.7%) (58), greenhouse workers (59),
latex glove manufacturers (sensitization prevalence
11%) (60, 61), housekeeping personnel and textile
workers, are also high risk.
Any individual who has ever developed a type
I reaction is at increased risk.
Children who have undergone multiple opera-
tions are at increased risk for latex sensitivity or
allergy (62-64). The younger the child at the time of
surgery, the higher the risk of developing latex
allergy. For that reason, children likely to require
surgical interventions during infancy should be
managed latex free from the very beginning of
life (65). Whether a patient, who has been operated
on frequently as an adult, is at increased risk, is still
matter of debate (59, 66-68). Spina bifida, even in
the absence of multiple surgical procedures, seems
to be an independent risk factor for latex sensitiza-
tion (69). Spina bifida patients show sensitization
prevalences ranging from 34% to 72% (66, 70).
DIAGNOSIS OF LATEX ALLERGY
1. The need for a good preoperative interview
To assess the risk for latex sensitization and
allergy, a specific preoperative interview is crucial.
Questions about the patient’s occupation, family
history of latex allergy, the presence of atopic
symptoms and symptoms such as itchiness, urti-
caria, conjunctivitis, rhinitis, asthma and angioede-
ma after contact with latex-containing products (for
example, after blowing up a balloon) are essential.
Any history of fruit allergy should also be looked
for. Asking about spina bifida and surgical proce-
dures at young age is also important because of the
link with the development of latex allergy.
2. Peroperative symptoms of latex allergy (vide supra)
Unlike anaphylaxis to anaesthetics, anaphy-
laxis to latex during anaesthesia usually presents 30
to 60 min after induction, coinciding with the
absorption of airborne allergens or with  mucous
membrane exposure at the beginning of the surgical
procedure. Cutaneous symptoms (such as rash,
urticaria and angioedema) are often masked by
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Table II
Risk groups for latex sensitization/allergy
1. Patients who have a history of atopy, in particular those with asth-
ma, dermatitis or food allergy
2. Patients exposed to repeated bladder catheterization. This group
includes children with neural tube defects (spina bifida) or urogen-
ital malformations
3. Healthcare workers and other occupations frequently exposed to
latex
4. Patients with a history of  anaphylaxis of uncertain aetiology, espe-
cially if associated with previous surgery, hospitalizations or den-
tal visits
5. Patients who have been operated on frequently at young age
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surgical drapes, while mild bronchoconstriction or
hypotension is often attributed to the administration
of medication or to normal physiological reactions
that can occur during anaesthesia. Consequently,
during  anaesthesia, bronchospasm and cardio-
vascular collapse are often the first signs of an
anaphylactic reaction.
The diagnosis of latex allergy should be con-
sidered in all cases of peroperative anaphylaxis,
even in patients without risk factors for latex aller-
gy, and all latex-containing materials should be
removed (71, 72).
3. Diagnostic tests
Preoperative testing is only done when there is
a family history of reactions or when patients expe-
rience symptoms such as a rash, swelling or wheez-
ing when exposed to latex. The investigation of a
suspected anaphylactic reaction is based on labora-
tory tests done during or shortly after the reaction
and on tests done days or weeks later.
3.a. Plasma concentrations of tryptase (RIA-
tryptase)
Several radioimmunoassay tests for the detec-
tion of histamine and tryptase are available (2).
The serum histamine concentration is not a
good test. An elevated plasma histamine does not
establish the mechanism of the reaction (73). In
addition, because of its short biological half-life,
the rise is usually transient and sampling must be
done at a time when resuscitation is a priority. 
An increased tryptase concentration in serum
is a marker for systemic mast cell activation.
Elevated β-tryptase concentrations are considered a
highly sensitive indicator of anaphylactic reactions
during anaesthesia (74), although they can be elev-
ated in other conditions (75). β-Tryptase concentra-
tions peak between 30 and 60 min ; thus they
should be measured approximately one hour after
the start of the reaction. The biological half-life is
estimated at 2 h, and therefore increased concentra-
tions can be detected for 1-6 h or more after the
onset of anaphylaxis. The more severe the anaphy-
lactic reaction, the higher the β-tryptase, but a neg-
ative result does not completely rule out anaphylax-
is, particularly if sampling is done at the beginning
of the reaction, or in mild reactions (74, 76). 
The sensitivity of the tryptase test for the diag-
nosis of anaphylaxis is 64%, the specificity is high :
89.3%. The positive predictive value is 92.6% ; the
negative predictive value is only 54.3% (2).
The diagnosis of anaphylaxis should not rely
on a single test, and patients in whom mast cell
tryptase concentrations are not increased still
require skin testing or latex-specific IgE measure-
ments (2).
3.b. In vitro test : radioimmunoassay for the
detection of latex-specific IgE antibodies
The FDA has approved three different serum
tests to detect and to quantify latex-specific IgEs
(CAP, ALaSTAT, HYTEC). These tests are highly
specific, but their sensitivity is low. They are less
sensitive than skin prick tests but can be used safe-
ly. The CAP and ALaSTAT have sensitivities that
range from 75% to 80%, and specificities that range
from 90% to 95% (77-79) : approximately 20-25%
of IgE-positive patients test as false negative. The
HYTEC shows a high sensitivity (90%), but a lower
specificity of 68-73% (79, 80) : approximately 30%
of the results are false positive.
Although classically made several weeks after
the reaction, these tests can be done on blood drawn
at the time of the reaction (43).
3.c. In vivo test : skin prick
In Europe a standardized fresh latex extract is
now available for skin prick tests (Stallergenes,
Paris, France) ; in America clinicians use a home-
made latex extract (for example made of latex
gloves) or a commercial extract. These extracts
have a sensitivity of 70-98% and a specificity of
more than 95% (81-83). So the sensitivity of the
skin prick test is better than in the detection of the
latex-specific IgEs.
Skin prick tests are not without danger and
anaphylaxis is reported (84-88). They are best done
4 to 6 weeks after the reaction. Immediately after
the anaphylactic reaction there is a depletion of
mast cell mediators, which can make the skin prick
test false negative.
Table III
Symptoms of latex exposure and possible anaphylaxis (9)
Conscious patient Anaesthetized patient
Itchy eyes Facial oedema
Generalized pruritus Urticaria
Shortness of breath Rash
Sneezing Skin flushing
Wheezing Bronchospasm
Nausea and/or vomiting Laryngeal oedema
Faintness Oedema
Abdominal cramping Hypotension
Diarrhoea Tachycardia
Feeling of impending doom Cardiac arrest
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3.d. Genetic testing
Some gene forms are associated with in-
creased risk for latex allergy (89-92). If the family
history is positive, genetic testing is advised to
identify persons before sensitization occurs.
3.e. Provocation tests
Several variants of provocation tests have been
described (93-94) : for example, wearing of latex
gloves, nasal or bronchial inhalation of latex parti-
cles. Unfortunately there is no standardization
between the protocols, so it is difficult to compare
these tests. 
Provocation tests should only be done when
rescuscitation equipment is available. Because of
the potential danger, this diagnostic method should
be reserved for patients with a clear history of latex
allergy, but in whom the skin test and the latex-spe-
cific IgE test remain negative (93). 
ANAESTHETIC POLICY IN A PATIENT WITH LATEX ALLERGY
Premedication with corticosteroids and H1-
and H2-antagonists is still controversial because is
does not prevent latex-mediated anaphylaxis (95,
96), and it can give the anaesthetist a false sense of
security. In high-risk patients, however, premedica-
tion can be recommended in addition to latex avoid-
ance since it may temper the severity of the reac-
tion. 
Absolute avoidance of contact with latex is
mandatory for all not yet sensitized patients belong-
ing to a risk group (primary prevention) and for all
sensitized patients (secondary prevention) (97-99).
There are specific points of interest in perioperative
primary and secondary prevention (9).
1. In every operation theatre, pre-anaesthetic
area or post-anaesthesia care unit (PACU), a list of
all products containing latex and appropriate latex-
free substitutes should be available. This list must
be exact and updated frequently. 
2. A trolley containing only latex-free materi-
als must be immediately available. It must be well
covered to prevent contamination with latex aeroal-
lergens.
3. Write a warning in the front of the patient’s
file and on the bed : ‘This patient has latex allergy’.
4. Inform all healthcare workers preoperatively
(anaesthetic department, nurses, surgeon).
5. Schedule the procedure as the first case of
the day, when the amounts of latex aeroallergens
are least. Prepare the operation room (OR) the
evening before (remove all latex-containing materi-
als, put the latex-free trolley and the latex-free sur-
gical materials ready, and inform the surgeon if no
latex-free substitute is available). Restrict move-
ments of staff and equipment before and during the
surgical procedure to minimize the concentration of
aeroallergens in the operation room.
6. If it is not possible to schedule the procedure
as the first case, do it in an operating room that has
not been used for a minimum of 6 h, to reduce opti-
mally the concentration of latex aeroallergens (97,
100). All upper surfaces should be thoroughly
cleaned.
7. Mark the OR doors with a clear warning :
‘Precautions, latex allergy’.
8. Resuscitation equipment should be immedi-
ately available.
9. Use only latex-free materials (gloves, perfu-
sion sets, syringes, blood pressure cuffs, bladder
catheter).
10. Release of cornstarch particles into the air
must be avoided. Powdered latex gloves must not be
opened or taken off in the room where the latex-
allergic patient is being treated. Those caring for the
allergic patient must wear fresh clothes and wash
their hands very carefully to avoid the transfer of
latex particles.
11. Use medications from glass ampoules or
latex-free vials if available. The use of medications
from vials with a latex-containing rubber stopper is
still controversial. Latex proteins can be released
from the stopper. The stopper must be removed and
the medication drawn up with a latex-free syringe
(101-103). Do not prick the stopper.
12. Monitor for anaphylactic reactions during
the whole procedure because these can occur up to
60 min after the exposure.
13. Inform PACU staff members in advance of
the patient’s arrival time. The patient is at risk for
anaphylaxis upon arrival in the PACU because of
aeroallergens or contact with latex particles from
the clothes or hands of the nurses. A patient with
latex allergy should be treated in a corner of the
PACU and should be treated by only one nurse.
PACU staff must follow the same hygiene prescrip-
tions as the OR staff.
PEROPERATIVE TREATMENT OF LATEX ALLERGIC REAC-
TIONS
Immediate recognition and aggressive treat-
ment of anaphylaxis is essential because mild symp-
toms may rapidly progress to severe shock. The
removal of the potential triggers of anaphylaxis is
necessary. All medication that could be responsible
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for the anaphylactic reaction (for example an infu-
sion with antibiotics) must be discontinued and the
environment must be converted to latex free. 
Intravascular volume expansion with isotonic
crystalloid or colloid is indicated for patients with
hypotension or shock. Adults receive boluses of 1 L
(total 25-50 ml/kg), children boluses of 20 ml/kg
(26). Adrenaline is the most important medication
for the treatment of anaphylaxis. Its α- and β-adren-
ergic effects result in an increase of the systemic
blood pressure, a reduction of the urticaria and the
angioedema, a relaxation of bronchial smooth mus-
cles, and a decrease of the mediator release of mast
cells and basophils. The dose and route used depend
on the severity of the episode. During anaesthesia,
intravenous administration is preferred. The recom-
mended initial dose is 5-10 µg IV (0.1 µg/kg), then
titrate to maintain an adequate systemic blood pres-
sure. In the presence of cardiovascular collapse,
adrenaline 0.1-0.5 mg IV should be given prompt-
ly (104), and continuous infusion of adrenaline and
noradrenaline may be required (105).
During local anaesthesia, intubation may be
become necessary. Administration of 100% oxygen
is mandatory as well as ventilation with positive
end-respiratory pressure.
After stabilization of the patient, an H1-block-
er, an H2-blocker and a corticosteroid such as
hydrocortisone or methylprednisolone should be
given to inhibit the effect, the production and the
release of mediators (106,107). Histamine mediates
the anaphylactic response through H1- and H2-
receptors. Corticosteroids are maximally effective
6 h after the reaction and can prevent delayed reac-
tions or the revival of an initially treated anaphylac-
tic reaction. Patients with upper airway obstruction
may benefit from an aerosol containing adrenaline.
Patients with bronchospasm can receive albuterol as
an adjuvant to the adrenaline (26). 
In patients taking β-blocking agents, the β-
adrenergic agonists have little effect.   Glucagon, if
available, has proved successful (108,109). The rec-
ommended  adult dose is 1 mg IV every 5 min until
the patient’s condition is stabilized, followed by a
continuous infusion.
Once the patient is stable, they should be
transferred to the intensive care unit and the serum
tryptase concentration tested.
DESENSITIZATION AND OTHER IMMUNOTHERAPIES
Several studies of progressive, controlled
administration of oral (110), cutaneous (111), sub-
cutaneous (112-114) and sublingual (115) latex
allergens show beneficial results in patients with
latex allergy, although these results need to be fur-
ther investigated.  Anaphylactic reactions are
reported (116). Latex-specific desensitization re-
mains an experimental treatment. The use of
humanized anti-IgE antibodies may play an impor-
tant part in the future treatment of latex allergy.
Others forms of immunotherapy are being studied.
CONCLUSION
The incidence of latex allergy has increased
consistently with time. The diagnosis should be
considered in all cases of perioperative anaphylax-
is, even in patients without risk factors for latex
allergy. With every perioperative anaphylactic reac-
tion the environment must be converted to be latex
free.
In the future it will probably be possible to
desensitize patients with latex allergy. At present,
the absolute avoidance of any contact with latex-
containing materials is the only way to treat these
patients safely.
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